Clinical Trial Update: Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 study of lenvatinib (E7080) in unresectable biliary tract cancer after failure of gemcitabine-based therapy has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• Lenvatinib (lenvatinib)

Snippet

Sponsor: Eisai Co., Ltd. | Conditions: Biliary Tract Cancer | Phase 2 | Status: COMPLETED | Results posted: 2020-12-23